170 related articles for article (PubMed ID: 8851600)
1. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Jones RN; Johnson DM; Erwin ME
Antimicrob Agents Chemother; 1996 Mar; 40(3):720-6. PubMed ID: 8851600
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Zurenko GE; Yagi BH; Schaadt RD; Allison JW; Kilburn JO; Glickman SE; Hutchinson DK; Barbachyn MR; Brickner SJ
Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
[TBL] [Abstract][Full Text] [Related]
3. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
Wise R; Andrews JM; Boswell FJ; Ashby JP
J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
5. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
[TBL] [Abstract][Full Text] [Related]
6. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
Eliopoulos GM; Wennersten CB; Gold HS; Moellering RC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1745-7. PubMed ID: 8807077
[TBL] [Abstract][Full Text] [Related]
8. Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
Muller-Serieys C; Drugeon HB; Etienne J; Lascols C; Leclercq R; Nguyen J; Soussy CJ
Clin Microbiol Infect; 2004 Mar; 10(3):242-6. PubMed ID: 15008946
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
Jorgensen JH; McElmeel ML; Trippy CW
Antimicrob Agents Chemother; 1997 Feb; 41(2):465-7. PubMed ID: 9021209
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
Henwood CJ; Livermore DM; Johnson AP; James D; Warner M; Gardiner A
J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of RU-66647, a new ketolide.
Jones RN; Biedenbach DJ
Diagn Microbiol Infect Dis; 1997; 27(1-2):7-12. PubMed ID: 9127099
[TBL] [Abstract][Full Text] [Related]
12. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
Biedenbach DJ; Jones RN
J Clin Microbiol; 1997 Dec; 35(12):3198-202. PubMed ID: 9399519
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
14. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
Jones RN; Ballow CH; Biedenbach DJ;
Diagn Microbiol Infect Dis; 2001; 40(1-2):59-66. PubMed ID: 11448565
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.
Mason EO; Lamberth LB; Kaplan SL
Antimicrob Agents Chemother; 1996 Apr; 40(4):1039-40. PubMed ID: 8849225
[TBL] [Abstract][Full Text] [Related]
16. Linezolid in vitro: mechanism and antibacterial spectrum.
Livermore DM
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii9-16. PubMed ID: 12730138
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.
Neu HC; Novelli A; Saha G; Chin NX
Antimicrob Agents Chemother; 1988 Apr; 32(4):580-3. PubMed ID: 3377467
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
[TBL] [Abstract][Full Text] [Related]
20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
